Current and future direct-acting antivirals against COVID-19

Research output: Contribution to journalArticlepeer-review


The coronavirus disease of 2019 (COVID-19) has caused an unprecedented global crisis. The etiological agent is a new virus called the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). As of October, 2020 there have been 45.4 million confirmed cases with a mortality rate of 2.6% globally. With the lack of a vaccine and effective treatments, the race is on to find a cure for the virus infection using specific antivirals. The viral RNA-dependent RNA polymerase, proteases, spike protein-host angiotensin-converting enzyme 2 binding and fusion have presented as attractive targets for pan-coronavirus and broad spectrum direct-acting antivirals (DAAs). This review presents a perspective on current re-purposing treatments and future DAAs.
Original languageEnglish
JournalFrontiers in Microbiology
Publication statusPublished - 12 Nov 2020


Dive into the research topics of 'Current and future direct-acting antivirals against COVID-19'. Together they form a unique fingerprint.

Cite this